Proposal for 5 new NIPERs sent to Ministry of Finance: Mansukh Mandaviya

Published On 2021-08-01 04:45 GMT   |   Update On 2021-08-01 04:45 GMT

New Delhi: In a major boost to the pharmaceutical education sector, the Minister of Chemicals and Fertilizers, Mansukh L. Mandaviya has revealed that an Expenditure Finance Committee (EFC) proposal has been sent to the Ministry of Finance for setting up five new National Institute of Pharmaceutical Education and Research (NIPERs) in the states of Tamil Nadu, Maharashtra, Chhattisgarh, Rajasthan, and Karnataka.

This came in response to a query about whether the government plans to establish four additional NIPERs during a question-and-answer session in the Lok Sabha on July 27th, 2021.

The Minister has also confirmed that a consolidated EFC proposal worth Rs. 4,300 crore has been sent to the Ministry of Finance for the strengthening and equipping of the existing seven NIPERs as well as the establishment of five new NIPERs for the period 2020-21 to 2024-25. In addition, the proposal included construction of the campuses, up-gradation of laboratories, setting up of Centres of Excellence, etc..

When asked if certain NIPERs do not have their own campuses and operate out of temporary structures, the Minister said that although NIPER Mohali and NIPER Guwahati have their own permanent campuses, construction on NIPER Ahmedabad has started in full swing.

At present, NIPERs in Ahmedabad, Hajipur, Hyderabad, Kolkata, and Raebareli are functioning from rented premises.

Continuing further, while providing the details of achievements made and funds spent on the functioning of the NIPER, Mandaviya mentioned that NIPERs are autonomous institutions having their own Board of Governors, which are responsible for the general superintendence, direction and control of the affairs of the Institute.

In addition to this, he also stated that as the institutes are mainly funded by the Government, it periodically reviews their functioning. The annual accounts of the Institute are also audited by the office of CAG. A third party evaluation of NIPERs through a private party has also been conducted.

"Further, the Expenditure Finance Committee (EFC) under the Ministry of Finance also appraises the functioning of NIPERs for their continuation/ expansion," the Minister added.

In continuation, he provided the following information on the National Institutional Rating Framework (NIRF) ranking of NIPERs in the "Pharmacy" category during the previous four years:

NIPERs

2017

2018

2019

2020

Mohali

2nd

1st

3rd

3rd

Hyderabad

5th

6th

6th

5th

Ahmedabad

-

14th

9th

8th

Guwahati

-

-

-

11th

Raebareli

-

-

-

18th

Kolkata

-

-

-

27th

Mandaviya also disclosed institute-specific information on students graduating, research papers that have been published, patents that have been submitted, and MOUs that have been signed, as shown below:

NIPER

Students passed out

Research Papers

published

Patents filed

MoU signed

Mohali

3,735

2,777

198

23

Ahmedabad

619

594

21

23

Hyderabad

1113

786

32

52

Guwahati

400

301

20

24

Kolkata

479

204

02

23

Raebareli

385

238

20

15

Hajipur

333

134

03

10

Total

7,064

5,034

296

178

Further, the following are the specifics of funds released to each NIPER by institute since their start (till June 2021): as under: 

NIPER

Funds released (Rs. in crore)

Mohali

406.54

Ahmedabad

195.77

Hyderabad

310.45

Guwahati

298.59

Kolkata

117.37

Raebareli

113.29

Hajipur

80.55

Total

1522.56

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News